SCHEMBL4568265

SCHEMBL4568265

FC(F)(F)c1ccc2cc(-c3ccsc3)[nH]c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.41
CDK5R1 Q15078 2/20 0.41
METAP2 P50579 1/20 0.40
PTGDR2 Q9Y5Y4 4/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
GSK3B P49841 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
TOP1 P11387 1/20 0.38
POLB P06746 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
IDH2 P48735 1/20 0.38
KIF11 P52732 4/20 0.38
NPBWR1 P48145 2/20 0.38
DGAT1 O75907 2/20 0.36
KCNH2 Q12809 2/20 0.36
LCK P06239 1/20 0.36
TXK P42681 1/20 0.36
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4884700 0.78 NPC1 (0.58) METAP2PTGDR2KIF11NPBWR1DGAT1
SCHEMBL17548599 0.77 PTGDR2 (0.46) METAP2PTGDR2CCNB2CDK1CCNB1
SCHEMBL4891906 0.74 NPC1 (0.61) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL4568036 0.73 NPC1 (0.51) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL4568279 0.72 TLR9 (0.40) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL4568266 0.72 CDK5 (0.43) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL4568271 0.71 CYP19A1 (0.62) CDK5CDK5R1METAP2PTGDR2KIF11
SCHEMBL4568299 0.71 CYP1A1 (0.42) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL4568267 0.71 CCNB2 (0.39) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL4568272 0.71 CCNB2 (0.39) CDK5CDK5R1CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R CDK5 1731/4885CDK5R1 402/4885METAP2 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.